SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced the appointment of Jeffrey W.
Henderson to its board of directors. Henderson brings nearly
30 years of financial, commercial and pharmaceutical industry
expertise to the board, most recently serving for almost 10 years
as chief financial officer of $100-billion health care products and services
company, Cardinal Health.
"We are delighted to appoint an industry executive of Jeff's
caliber to the Halozyme board," said Dr. Helen Torley, president and chief executive
officer. "Jeff brings great depth from his business experience in
strategy, finance, M&A and commercial operations that will
complement our board's expertise as we grow the company and prepare
for the potential commercialization of our investigational new
oncology drug, PEGPH20."
Henderson served as CFO of Cardinal Health from 2005 until late
last year, playing a key role in the company's growth and
transformation. During his tenure, the company acquired more than
30 companies, spun-off or sold multi-billion-dollar businesses and
expanded into new geographies and market segments. In addition to
his financial responsibilities, Henderson also managed commercial
operations in China and
Canada.
Prior to Cardinal Health, Henderson was president and general
manager of Eli Lilly Canada Inc. and vice president and corporate
controller of Eli Lilly & Co. He joined Lilly in 1998 as vice
president and corporate treasurer. His prior experience included 10
years at General Motors Corp., where he served executive and
managerial posts in Great Britain,
Singapore, New York and Canada. He received his Bachelor of Science
degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business
Administration degree from Harvard Graduate School of Business
Administration. Henderson is a native of St. Catharines, Ontario, Canada.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, metastatic breast
cancer and has potential across additional cancers in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug
delivery platform, ENHANZEâ„¢, which enables biologics and small
molecule compounds that are currently administered intravenously to
be delivered subcutaneously. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the Company's future expectations
and plans for growth in 2015, the development and commercialization
of product candidates and the potential benefits and attributes of
such product candidates and expected financial outlook for 2015)
that involve risk and uncertainties that could cause actual results
to differ materially from those in the forward-looking statements.
The forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected expenditures and costs, unexpected
fluctuations or changes in revenues from collaborators, unexpected
results or delays in development and regulatory review, regulatory
approval requirements, unexpected adverse events and competitive
conditions. These and other factors that may result in differences
are discussed in greater detail in the Company's Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on
May 11, 2015.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-appoints-jeffrey-w-henderson-to-board-300124375.html
SOURCE Halozyme Therapeutics, Inc.